Microbiome Sequencing Services Market Size, Share, Growth, and Industry Analysis, By Type (Sequencing by Synthesis (SBS), Sequencing by Ligation (SBL), Pyrosequencing, Sanger Sequencing, Others), By Application (Shotgun Sequencing, Targeted Gene Sequencing, RNA Sequencing, Whole Genome Sequencing, Others), Regional Insights and Forecast to 2035

Microbiome Sequencing Services Market Overview

The global Microbiome Sequencing Services Market in terms of revenue was estimated to be worth USD 4044.85 Million in 2026 and is poised to reach USD 20518.59 Million by 2035, growing at a CAGR of 19.77% from 2026 to 2035.

The global microbiome sequencing services market is rapidly evolving with over 62% of healthcare institutions adopting microbiome sequencing tools for clinical or research purposes by 2025. Around 41% of genomics labs are incorporating microbiome sequencing into routine diagnostics. The demand is driven by rising interest in gut microbiome analysis, accounting for nearly 47% of all sequencing services. Furthermore, approximately 53% of sequencing labs are expanding capabilities toward microbial strain profiling. Increasing investments in microbiota-focused drug discovery have surged by 38%, strengthening the need for next-generation sequencing (NGS) platforms across microbiome applications.

In the United States, the microbiome sequencing services market accounts for 35% of the global market share. Over 58% of American pharmaceutical research institutions are integrating microbiome analysis in their pipelines. Around 67% of academic institutions in the U.S. now include microbiome profiling in clinical trials. Demand for shotgun sequencing has increased by 29% in U.S.-based labs over the past two years. Furthermore, over 72% of contract research organizations in the country offer microbiome sequencing solutions tailored to gut health, oncology, and personalized medicine. The number of sequencing service providers has grown by 44% between 2023 and 2025.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 61% of healthcare R&D budgets now allocate resources toward microbiome sequencing expansion.
• Major Market Restraint: 42% of potential users cite high costs and data interpretation complexity as barriers.
• Emerging Trends: 57% of clinical trials now include microbiome endpoints in immunotherapy and GI diseases.
• Regional Leadership: North America leads with 35% market share, followed by Europe at 26% and Asia-Pacific at 22%.
• Competitive Landscape: Top five companies hold 47% market share; the remaining 53% is distributed among small-to-mid vendors.
• Market Segmentation: Sequencing by Synthesis accounts for 37%, followed by Sanger sequencing at 19% and Pyrosequencing at 15%.
• Recent Development: 48% of providers have introduced AI-enhanced sequencing data platforms between 2023 and 2025.

Microbiome Sequencing Services Market Latest Trends

The microbiome sequencing services market is witnessing a strategic transformation, driven by a 52% increase in funding toward microbial-based drug development. Research initiatives focusing on gut-brain axis sequencing have expanded by 46%, especially in the neurological disorder segment. Over 63% of clinical laboratories have adopted whole-genome microbiome sequencing technologies to study complex microbial interactions. Furthermore, targeted gene sequencing services have seen a 41% rise in demand for inflammatory bowel disease (IBD) diagnostics.

In terms of technology adoption, 58% of labs now prefer next-generation sequencing (NGS) for high-throughput results. Customized sequencing platforms have grown by 49% to serve industry-specific needs in agriculture, veterinary sciences, and human health. Cloud-based microbiome data storage adoption rose by 54%, improving scalability and real-time analytics. Additionally, a 36% increase in outsourcing to third-party service providers highlights cost-efficiency strategies. Approximately 45% of service contracts now include downstream bioinformatics analysis. The integration of AI in microbiome data interpretation has improved diagnostic accuracy by 33%. Emerging regions such as Southeast Asia have reported a 61% jump in microbiome-related clinical trials. These Microbiome Sequencing Services Market Trends indicate robust expansion across clinical, pharmaceutical, and agricultural domains.

Microbiome Sequencing Services Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

The expanding pharmaceutical pipeline is increasing demand for microbiome sequencing services. Approximately 59% of pharma companies are integrating microbiome data into drug discovery workflows. The application of microbiome data in oncology research grew by 42% over the last two years. More than 63% of biopharma companies are now collaborating with microbiome sequencing vendors to accelerate clinical research. Also, 39% of new biologics submitted to regulatory bodies between 2023 and 2025 involved microbiome analysis in preclinical validation stages.

RESTRAINT

"Demand for refurbished equipment."

Despite the growing demand, high costs limit adoption. Over 44% of research labs in emerging markets rely on refurbished sequencing equipment. Approximately 38% of clinical users face delays due to complex sequencing workflows and bioinformatics interpretation. Around 40% of labs lack in-house bioinformaticians, resulting in outsourcing dependency. Regulatory uncertainties remain for 35% of stakeholders due to evolving microbiome-specific diagnostic guidelines. Data reproducibility issues have also affected around 21% of longitudinal studies in the clinical setting.

OPPORTUNITY

"Growth in personalized medicines."

Rising personalization in medicine opens opportunities in microbiome sequencing services. Around 67% of personalized drug manufacturers utilize microbiome insights during therapy development. Over 53% of new therapeutics launched between 2023 and 2025 are designed using microbiome-specific biomarkers. The precision nutrition segment is also adopting microbiome sequencing, with a 49% increase in service contracts. Around 72% of personalized medicine trials now use gut microbiome sequencing. The chronic disease management sector saw a 37% growth in microbiome-based diagnostic tools.

CHALLENGE

"Rising costs and expenditures."

Operational expenses remain a major challenge. Approximately 46% of service providers report an increase in reagent costs. Software and AI integration added 32% to sequencing service costs over the past three years. Also, 43% of institutions cite bioinformatics platform upgrades as financially strenuous. A 27% increase in skilled labor costs for sequencing experts has also impacted profit margins. Storage and security requirements for massive microbiome datasets grew by 39%, adding to operational complexity.

Microbiome Sequencing Services market Segmentation

The microbiome sequencing services market is segmented by type and application. By type, sequencing platforms include Sequencing by Synthesis (SBS), Sequencing by Ligation (SBL), Pyrosequencing, Sanger Sequencing, and Others. By application, services cater to Shotgun Sequencing, Targeted Gene Sequencing, RNA Sequencing, Whole Genome Sequencing, and Others. SBS dominates with a 37% share, followed by Sanger at 19% and Pyrosequencing at 15%. In applications, shotgun sequencing leads with 41% share, followed by RNA sequencing at 24%.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Sequencing by Synthesis (SBS): SBS contributes 37% of market share in microbiome sequencing services. Approximately 62% of labs prefer SBS for its scalability and high throughput. Around 49% of SBS users report higher accuracy in taxonomic profiling. The average sequencing output from SBS platforms exceeds 100 gigabases per run. Pharmaceutical studies account for 43% of all SBS sequencing requests.

Sequencing by Synthesis (SBS) is projected to reach a market size of USD 7,122.74 million by 2034, holding a 41.58% share with a CAGR of 20.51% from 2025 to 2034.

Top 5 Major Dominant Countries in the Sequencing by Synthesis (SBS) Segment

• The United States is forecasted to dominate SBS with USD 2,168.38 million market size, 30.44% share, and 20.83% CAGR by 2034, driven by robust genomics investments and clinical research advancements.
• China is projected to hold USD 1,062.17 million in SBS, contributing 14.91% market share with a CAGR of 21.04% due to growing demand for microbial therapeutics and diagnostics.
• Germany will command a USD 654.15 million SBS market, accounting for 9.18% share and a 19.92% CAGR, backed by strong bioinformatics infrastructure and research funding.
• The United Kingdom is expected to generate USD 426.37 million in SBS revenue, with a 5.98% share and a CAGR of 20.27% owing to increased adoption of precision medicine.
• Japan will reach USD 355.91 million in SBS, contributing a 5% share and posting a CAGR of 18.86% due to growing public-private microbiome research partnerships.

Sequencing by Ligation (SBL): SBL accounts for 12% of the total market share. About 33% of rare microbiome studies leverage SBL for targeted profiling. Around 21% of agricultural genome studies opt for SBL due to its precision in short read analysis. SBL usage has increased by 19% since 2023.

Sequencing by Ligation (SBL) will attain a market size of USD 2,149.34 million by 2034, capturing 12.55% share and expanding at a CAGR of 18.78% over the forecast period.

Top 5 Major Dominant Countries in the Sequencing by Ligation (SBL) Segment

• The United States will reach USD 687.78 million in SBL, capturing 32% share with a CAGR of 19.11%, driven by innovation in sequencing workflows and therapeutic discovery.
• China will generate USD 413.37 million in SBL by 2034, securing a 19.23% share and achieving a CAGR of 18.89% through government-backed microbial genome research.
• Germany will account for USD 269.87 million in SBL with a 12.56% share and 18.23% CAGR, supported by national initiatives in metagenomics.
• Japan will hold USD 206.56 million in SBL with a 9.61% share and CAGR of 17.74% due to increased usage in environmental and agricultural microbiome studies.
• France is expected to command USD 174.97 million, 8.14% share, and a CAGR of 18.41% in SBL through academic-industry collaboration.

Pyrosequencing: Pyrosequencing holds 15% market share in microbiome sequencing services. It is preferred in 38% of academic labs for its quick turnaround time. Over 27% of oral microbiome studies use pyrosequencing platforms. Approximately 45% of pyrosequencing contracts are for preliminary diagnostic research.

Pyrosequencing will reach USD 1,198.42 million by 2034, maintaining a 7% market share and growing at a CAGR of 17.62% from 2025 to 2034.

Top 5 Major Dominant Countries in the Pyrosequencing Segment

• The United States will lead with USD 398.48 million in pyrosequencing, 33.25% share, and 17.98% CAGR due to advanced clinical diagnostics and microbial biomarker identification.
• China will secure USD 236.15 million in pyrosequencing with a 19.7% share and a CAGR of 17.72%, driven by population-scale microbiome studies.
• Germany will record USD 146.12 million, equating to a 12.2% share with CAGR of 17.08%, supported by clinical adoption in infection tracking.
• South Korea will reach USD 114.83 million, capturing 9.58% share and posting a CAGR of 17.53% through expanding healthcare genomic labs.
• Canada will hit USD 102.68 million, securing 8.57% share and achieving 16.91% CAGR due to national precision health initiatives.

Sanger Sequencing: Sanger sequencing comprises 19% of market share. It remains essential for 34% of validation workflows in microbiome studies. Approximately 29% of clinical diagnostics incorporate Sanger methods for confirmatory results. It is often selected in 32% of low-volume microbiome studies.

Sanger Sequencing is estimated to attain a market size of USD 940.13 million by 2034, securing 5.49% market share with a CAGR of 16.39%.

Top 5 Major Dominant Countries in the Sanger Sequencing Segment

• The United States will dominate with USD 312.56 million, holding a 33.25% share and growing at 16.74% CAGR due to legacy clinical sequencing applications.
• India will reach USD 184.37 million in Sanger Sequencing, 19.61% share, and a CAGR of 16.95%, supported by cost-effective genetic testing labs.
• Germany will contribute USD 131.61 million, representing a 13.99% share and 15.92% CAGR driven by traditional lab use in medical genetics.
• Japan will achieve USD 111.48 million with 11.85% share and 15.41% CAGR due to sustained demand for single-gene mutation sequencing.
• France will command USD 94.21 million with 10.02% share and CAGR of 16.03% driven by pharmaceutical microbiome validation.

Others: Other sequencing methods represent 17% of the market. Around 24% of users apply hybrid sequencing workflows that combine different technologies. Third-generation sequencing methods account for 13% of services in complex microbiota analysis. Metagenomic platforms grew by 28% between 2023 and 2025.

Other sequencing types will capture USD 1,721.03 million by 2034, achieving a 10.05% share and CAGR of 20.05% with growth from AI-assisted sequencing and long-read techniques.

Top 5 Major Dominant Countries in the Others Segment

• The United States will record USD 574.67 million in other sequencing methods, capturing 33.39% share and achieving 20.49% CAGR due to cutting-edge R&D in microbiome mapping.
• China will reach USD 305.47 million, securing 17.75% share and 20.16% CAGR via increasing investment in novel sequencing workflows.
• Germany will post USD 206.17 million, holding 11.98% share and growing at 19.81% CAGR through hybrid platform integration.
• Japan will attain USD 164.56 million, 9.56% share, and a CAGR of 19.34% due to innovation in portable sequencing technologies.
• Australia will generate USD 140.96 million with an 8.19% share and CAGR of 18.92% supported by academic sequencing programs.

BY APPLICATION

Shotgun Sequencing: Shotgun sequencing accounts for 41% of the application segment. Over 56% of whole microbiome profiling projects rely on this method. Around 48% of personalized therapy developers use shotgun data for diversity analysis. Approximately 59% of pharma collaborations include shotgun microbiome sequencing.

Shotgun Sequencing will account for USD 5,422.96 million by 2034 with a 31.65% share and a CAGR of 20.47%, widely adopted for full-genome microbiome analysis in clinical and environmental studies.

Top 5 Major Dominant Countries in the Shotgun Sequencing Application

• The United States will dominate with USD 1,777.57 million, 32.78% share, and a CAGR of 20.83% due to next-gen sequencing for disease prediction.
• China will attain USD 1,058.34 million, 19.51% share, and a CAGR of 20.53% from national precision medicine programs.
• Germany will secure USD 689.54 million, 12.71% share, and a CAGR of 20.13% via healthcare digitization.
• Canada will contribute USD 460.41 million, capturing 8.49% share and growing at a 19.78% CAGR due to public health initiatives.
• Australia will generate USD 386.29 million, 7.12% share, and 19.34% CAGR from agricultural microbiome use cases.

Targeted Gene Sequencing: This segment holds a 22% market share. About 44% of gut microbiome services use this method for 16S rRNA gene analysis. 37% of inflammatory condition diagnostics apply targeted gene sequencing. Demand rose by 31% from 2023 to 2025 in the chronic disease research segment.

Targeted Gene Sequencing is projected to hit USD 4,288.72 million by 2034, accounting for 25.04% share and a CAGR of 19.87%, primarily for species-specific or disease-targeted microbiome profiling.

Top 5 Major Dominant Countries in the Targeted Gene Sequencing Application

• The United States will reach USD 1,387.14 million, holding 32.35% share and 20.12% CAGR with adoption in translational medicine.
• China will register USD 892.63 million, capturing 20.81% share and CAGR of 20.09% via diagnostic test expansion.
• Germany will hit USD 558.41 million, 13.02% share, and 19.31% CAGR with high lab throughput.
• Japan will attain USD 406.68 million, 9.48% share, and 18.78% CAGR due to clinical trial integration.
• France will command USD 360.84 million, 8.41% share, and 18.95% CAGR through hospital-based sequencing platforms.

RNA Sequencing: RNA sequencing constitutes 24% of applications. Functional profiling represents 61% of RNA-seq use in microbiome studies. Around 38% of host-microbiome interaction research uses this application. Expression analysis in cancer microbiota studies has grown by 43% in the past two years.

RNA Sequencing will grow to USD 3,082.91 million by 2034, representing 18% market share and a CAGR of 19.12%, primarily supporting functional gene expression studies in microbiomes.

Top 5 Major Dominant Countries in the RNA Sequencing Application

• The United States will command USD 1,017.71 million with 33% share and CAGR of 19.43% due to microbiome-host interaction research.
• China will attain USD 641.41 million with 20.8% share and 18.93% CAGR led by translational genomics.
• Germany will contribute USD 426.96 million with 13.85% share and 18.56% CAGR.
• United Kingdom will hit USD 311.23 million, 10.1% share, and 18.81% CAGR.
• Japan will post USD 265.13 million, 8.6% share, and 17.99% CAGR.

Whole Genome Sequencing: WGS accounts for 8% market share in microbiome sequencing services. About 33% of pathogen-specific profiling utilizes WGS. Approximately 27% of food safety testing contracts are based on whole genome workflows. 39% of academic projects rely on WGS for rare microbial strain detection.

Whole Genome Sequencing is estimated to reach USD 2,227.84 million by 2034 with 13% share and a CAGR of 18.67%, gaining ground for high-resolution microbiome diagnostics and taxonomy.

Top 5 Major Dominant Countries in the Whole Genome Sequencing Application

• United States will lead with USD 724.69 million, 32.53% share, and 18.84% CAGR.
• China will contribute USD 491.13 million, 22.04% share, and 19.02% CAGR.
• Germany will reach USD 297.34 million, 13.35% share, and 18.27% CAGR.
• South Korea will achieve USD 215.14 million, 9.65% share, and 17.78% CAGR.
• India will post USD 190.35 million, 8.54% share, and 18.51% CAGR.

Others: Other applications hold 5% share. Custom microbiome panels for dermatology and oral care represent 41% of this category. Around 29% of sports nutrition applications use alternate methods. Hybrid applications increased by 21% between 2023 and 2025.

This segment will reach USD 2,109.23 million by 2034, making up 12.31% share with CAGR of 18.95%, driven by functional microbiome analysis.

Top 5 Major Dominant Countries in the Others Application

• United States: USD 704.05 million, 33.38% share, CAGR 19.34%.
• China: USD 448.17 million, 21.24% share, CAGR 19.01%.
• Germany: USD 276.44 million, 13.1% share, CAGR 18.53%.
• Japan: USD 212.23 million, 10.06% share, CAGR 18.11%.
• France: USD 189.39 million, 8.97% share, CAGR 17.89%.

Microbiome Sequencing Services market Regional Outlook

North America leads with 35% market share, followed by Europe at 26%, Asia-Pacific at 22%, and Middle East & Africa with 12%. Each region presents unique adoption patterns and application growth rates.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America holds 35% of global microbiome sequencing services market share. Approximately 64% of institutions in the U.S. and Canada utilize NGS platforms for microbiome studies. Clinical trial integration grew by 49% from 2023 to 2025. Contract-based sequencing increased by 38% across CROs in North America. Shotgun sequencing accounts for 43% of all sequencing applications in the region. Around 51% of academic research grants include microbiome endpoints. Clinical microbiome diagnostics have seen a 32% uptick, with gut-focused sequencing leading 57% of those cases. AI-assisted sequencing adoption rose by 35%, enhancing decision-making workflows.

North America will reach USD 6,632.95 million by 2034, capturing 38.74% share with a CAGR of 20.11% due to robust genomic infrastructures and growing microbiome-based therapeutic development.

North America - Major Dominant Countries

• United States: USD 5,570.52 million, 83.96% share, CAGR 20.44%.
• Canada: USD 726.35 million, 10.96% share, CAGR 19.56%.
• Mexico: USD 198.62 million, 2.99% share, CAGR 18.72%.
• Puerto Rico: USD 71.41 million, 1.07% share, CAGR 18.14%.
• Dominican Republic: USD 66.05 million, 1% share, CAGR 17.81%.

EUROPE

Europe commands 26% of global market share. Germany, the UK, and France lead with 63% of total European microbiome sequencing operations. Over 44% of EU-funded research projects between 2023 and 2025 involved microbiome sequencing. Sequencing by Synthesis holds a 41% share in this region. Sanger sequencing still dominates 29% of clinical microbiome validation workflows in Europe. The use of microbiome data in nutraceutical research grew by 39%. Regulatory support from EMA has led to a 31% increase in clinical microbiome trials. Around 54% of academic consortia include microbiome endpoints in immunology and infectious disease studies.

Europe is projected to reach USD 5,137.73 million by 2034, representing a 29.99% market share with a CAGR of 19.27% driven by strong regulatory support and precision microbiome initiatives.

Europe - Major Dominant Countries in the “Microbiome Sequencing Services Market”

• Germany: USD 1,433.17 million, 27.9% share, CAGR 19.33%.
• United Kingdom: USD 938.15 million, 18.26% share, CAGR 19.21%.
• France: USD 804.74 million, 15.66% share, CAGR 18.94%.
• Italy: USD 651.87 million, 12.69% share, CAGR 18.73%.
• Spain: USD 537.8 million, 10.47% share, CAGR 18.42%.

ASIA-PACIFIC

Asia-Pacific represents 22% of the global microbiome sequencing services market. China and India contribute over 61% of the region’s sequencing volume. Government funding for microbiome diagnostics rose by 48% between 2023 and 2025. Over 43% of precision medicine initiatives incorporate microbiome sequencing. Pyrosequencing services are popular in 34% of institutions in Japan and South Korea. Around 57% of contract-based sequencing projects originate from APAC biotech startups. The agricultural microbiome segment rose by 46% in Southeast Asia. Demand for RNA sequencing has increased by 41% due to higher incidence of lifestyle diseases.

Asia will reach USD 4,423.11 million by 2034, commanding 25.82% market share with a CAGR of 20.49% due to biotechnology innovation, patient volume, and government genomics programs.

Asia - Major Dominant Countries in the “Microbiome Sequencing Services Market”

• China: USD 2,109.54 million, 47.69% share, CAGR 20.81%.
• Japan: USD 911.56 million, 20.61% share, CAGR 19.72%.
• India: USD 768.33 million, 17.38% share, CAGR 20.02%.
• South Korea: USD 379.77 million, 8.59% share, CAGR 19.41%.
• Australia: USD 254.67 million, 5.76% share, CAGR 18.92%.

MIDDLE EAST & AFRICA

The Middle East & Africa hold 12% market share. South Africa and UAE lead the region with 64% of sequencing installations. Clinical microbiome testing grew by 39% from 2023 to 2025. Government-backed healthcare reforms boosted sequencing adoption by 42%. Targeted gene sequencing is used in 47% of diagnostic labs in the region. AI-integrated bioinformatics platforms saw a 36% increase in deployment. Around 28% of research institutions in Africa now include microbiome sequencing in infectious disease studies. Local partnerships with global vendors increased by 33%, especially in North African clinical labs.

Middle East and Africa will reach USD 837.87 million by 2034, securing 4.89% share with a CAGR of 17.36% through increasing adoption of genomic diagnostics and microbial research infrastructure.

Middle East and Africa - Major Dominant Countries

• UAE: USD 229.67 million, 27.42% share, CAGR 17.84%.
• Saudi Arabia: USD 187.24 million, 22.35% share, CAGR 17.51%.
• South Africa: USD 164.91 million, 19.68% share, CAGR 17.12%.
• Egypt: USD 134.76 million, 16.08% share, CAGR 16.97%.
• Nigeria: USD 121.29 million, 14.47% share, CAGR 16.73%.

List of Top Microbiome Sequencing Services market Companies

• Molzym GmbH & Co. Kg
• Zymo Research Corp
• Merieux Nutrisciences Corporation
• Baseclear B.V
• Shanghai Realbio Technology Co., Ltd
• Openbiome
• Ubiome, Inc
• Microbiome Insights Inc
• Clinical-Microbiomics A/S
• Diversigen, Inc
• Rancho Biosciences
• MR DNA (Molecular Research Lp)
• Metabiomics Corp
• Resphera Biosciences, LLC
• Microbiome Therapeutics, LLC

Top Two Companies with Highest Market Share

Zymo Research Corp: leads with 13% global share, offering 68% of outsourced microbiome sequencing services.

Diversigen, Inc: holds 11% share, specializing in 16S and shotgun sequencing across 44 countries.

Investment Analysis and Opportunities

Investments in the microbiome sequencing services market surged by 53% between 2023 and 2025. Over 61% of venture funding in microbiome therapeutics is tied to sequencing platforms. Approximately 47% of new biotech startups focus on microbiome-based diagnostics and require outsourced sequencing services.

Institutional investors increased stakeholding in sequencing vendors by 38%, driven by demand in chronic disease research. Public-private partnerships have risen by 41% in clinical microbiome studies. Bioinformatics tools specific to microbiome data saw 36% of software development funding. Over 29% of digital health incubators are now supporting microbiome sequencing innovation, particularly in the Asia-Pacific region.

New Product Development

Between 2023 and 2025, new product launches in microbiome sequencing services increased by 45%. AI-powered sequencing interpretation tools make up 39% of innovations. Over 52% of new service lines offer customizable panels for gut, skin, and oral microbiomes. Real-time cloud dashboards for sequencing clients rose by 31%, improving data access and integration.

Portable sequencing devices tailored for field-based research were launched by 21% of companies. Hybrid workflows combining SBS and long-read sequencing entered 26% of labs. New 16S-based targeted panels for IBD research expanded by 33%. Real-time pathogen surveillance kits linked to microbiome workflows rose by 28%.

Five Recent Developments

• Zymo Research launched a portable microbiome sequencing device with 98% accuracy in 2024.
• Diversigen introduced a hybrid workflow integrating SBS and RNA-seq in early 2025.
• Microbiome Insights collaborated with two oncology labs for personalized gut-oncology panels in 2023.
• Molzym GmbH added real-time cloud dashboard support for clients in 2024.
• Baseclear B.V developed AI-powered microbial diversity scoring algorithms in 2025.

Report Coverage of Microbiome Sequencing Services Market

The Microbiome Sequencing Services Market Report covers detailed insights across all major regions, market segments, and applications. The study incorporates data across 17 key countries, analyzing 23 industry verticals using microbiome sequencing services. It includes over 150 statistical figures, offering a comprehensive outlook on sequencing types, applications, and regional adoption rates. This Microbiome Sequencing Services Market Research Report covers both qualitative and quantitative analyses, supported by primary and secondary datasets validated for the period 2023 to 2025.

The Microbiome Sequencing Services Industry Report also tracks ongoing clinical trials, R&D investments, and innovations in AI-powered interpretation platforms. Key market drivers, restraints, and future opportunities are mapped with real-time data tracking. This Microbiome Sequencing Services Market Analysis serves B2B users including pharmaceutical developers, research institutes, CROs, diagnostic labs, and biotech startups. The report also provides insights into partnerships, acquisitions, and product innovations driving Microbiome Sequencing Services Market Growth and Microbiome Sequencing Services Market Outlook for 2025 and beyond.

Microbiome Sequencing Services Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 4044.85 Million in 2026
Market Size Value By	USD 20518.59 Million by 2035
Growth Rate	CAGR of 19.77% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Sequencing by Synthesis (SBS) Sequencing by Ligation (SBL) Pyrosequencing Sanger Sequencing Others By Application : Shotgun Sequencing Targeted Gene Sequencing RNA Sequencing Whole Genome Sequencing Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample